Survival following salvage therapy for primary refractory peripheral T‐cell lymphomas (PTCL)
dc.contributor.author | Zhang, Janie Y. | |
dc.contributor.author | Briski, Robert | |
dc.contributor.author | Devata, Sumana | |
dc.contributor.author | Kaminski, Mark S. | |
dc.contributor.author | Phillips, Tycel J. | |
dc.contributor.author | Mayer, Tera L. | |
dc.contributor.author | Bailey, Nathanael G. | |
dc.contributor.author | Wilcox, Ryan A. | |
dc.date.accessioned | 2018-03-07T18:25:04Z | |
dc.date.available | 2019-05-13T14:45:24Z | en |
dc.date.issued | 2018-03 | |
dc.identifier.citation | Zhang, Janie Y.; Briski, Robert; Devata, Sumana; Kaminski, Mark S.; Phillips, Tycel J.; Mayer, Tera L.; Bailey, Nathanael G.; Wilcox, Ryan A. (2018). "Survival following salvage therapy for primary refractory peripheral T‐cell lymphomas (PTCL)." American Journal of Hematology 93(3): 394-400. | |
dc.identifier.issn | 0361-8609 | |
dc.identifier.issn | 1096-8652 | |
dc.identifier.uri | https://hdl.handle.net/2027.42/142498 | |
dc.description.abstract | Optimal salvage therapy for primary refractory peripheral T‐cell lymphomas (PTCL) and the role of hematopoietic stem cell transplant (SCT) remain poorly defined. We conducted a retrospective review of clinical outcomes and prognostic factors in a single‐center cohort of 93 patients with primary refractory PTCL, defined as progression during first‐line therapy or relapse within 6 months of its completion. Clinical outcomes were poor in this population, with median event‐free survival (EFS) of 3.5 months, median overall survival (OS) of 9.1 months, and 34% 3‐year survival. Outcomes were comparable in patients who progressed through first‐line therapy and patients who achieved CR/PR and subsequently relapsed within 6 months. A majority exhibited high‐risk features and had intermediate to high risk IPI, which correlated with inferior outcomes. There was no difference in outcomes between patients who received single‐agent salvage regimens and patients who underwent traditional, multi‐agent salvage regimens. Thus, participation in well‐designed clinical trials should be encouraged in this population. Additionally, there may be a trend toward improved EFS and OS in patients who underwent autologous or allogeneic SCT compared to patients who achieved CR or PR but were not transplanted. | |
dc.publisher | Wiley Periodicals, Inc. | |
dc.publisher | American Society of Hematology | |
dc.title | Survival following salvage therapy for primary refractory peripheral T‐cell lymphomas (PTCL) | |
dc.type | Article | en_US |
dc.rights.robots | IndexNoFollow | |
dc.subject.hlbsecondlevel | Oncology and Hematology | |
dc.subject.hlbsecondlevel | Molecular, Cellular and Developmental Biology | |
dc.subject.hlbtoplevel | Health Sciences | |
dc.subject.hlbtoplevel | Science | |
dc.description.peerreviewed | Peer Reviewed | |
dc.description.bitstreamurl | https://deepblue.lib.umich.edu/bitstream/2027.42/142498/1/ajh24992.pdf | |
dc.description.bitstreamurl | https://deepblue.lib.umich.edu/bitstream/2027.42/142498/2/ajh24992_am.pdf | |
dc.identifier.doi | 10.1002/ajh.24992 | |
dc.identifier.source | American Journal of Hematology | |
dc.identifier.citedreference | Wang T, Lu Y, Polk A, et al. T‐cell Receptor Signaling Activates an ITK/NF‐κB/GATA‐3 axis in T‐cell Lymphomas Facilitating Resistance to Chemotherapy. Clin Cancer Res. 2017; 23: 2506 – 2515. | |
dc.identifier.citedreference | Mak V, Hamm J, Chhanabhai M, et al. Survival of patients with peripheral T‐cell lymphoma after first relapse or progression: spectrum of disease and rare long‐term survivors. J Clin Oncol. 2013; 31: 1970 – 1976. | |
dc.identifier.citedreference | Briski R, Feldman AL, Bailey NG, et al. Survival in patients with limited‐stage peripheral T‐cell lymphomas. Leuk Lymphoma. 2015; 56 ( 6 ): 1665 – 1670. | |
dc.identifier.citedreference | Abramson JS, Feldman T, Kroll‐Desrosiers AR, et al. Peripheral T‐cell lymphomas in a large US multicenter cohort: prognostication in the modern era including impact of frontline therapy. Ann Oncol. 2014; 25 ( 11 ): 2211 – 2217. | |
dc.identifier.citedreference | d’Amore F, Relander T, Lauritzsen GF, et al. Up‐front autologous stem‐cell transplantation in peripheral T‐cell lymphoma: NLG‐T‐01. J Clin Oncol. 2012; 30: 3093 – 3099. | |
dc.identifier.citedreference | O’Connor OA, Pro B, Pinter‐Brown L, et al. Pralatrexate in patients with relapsed or refractory peripheral T‐cell lymphoma: results from the pivotal PROPEL study. J Clin Oncol. 2011; 29: 1182 – 1189. | |
dc.identifier.citedreference | Pro B, Horwitz SM, Prince HM, et al. Romidepsin induces durable responses in patients with relapsed or refractory angioimmunoblastic T‐cell lymphoma. Hematol Oncol. 2016 [Epub ahead of print]. | |
dc.identifier.citedreference | Coiffier B, Pro B, Prince HM, et al. Romidepsin for the treatment of relapsed/refractory peripheral T‐cell lymphoma: pivotal study update demonstrates durable responses. J Hematol Oncol. 2014; 7 ( 1 ): 11. | |
dc.identifier.citedreference | Piekarz RL, Frye R, Prince HM, et al. Phase 2 trial of romidepsin in patients with peripheral T‐cell lymphoma. Blood. 2011; 117 ( 22 ): 5827 – 5834. | |
dc.identifier.citedreference | Foss F, Advani R, Duvic M, et al. A Phase II trial of Belinostat (PXD101) in patients with relapsed or refractory peripheral or cutaneous T‐cell lymphoma. Br J Haematol. 2015; 168 ( 6 ): 811 – 819. | |
dc.identifier.citedreference | O’Connor OA, Horwitz S, Masszi T, et al. Belinostat in patients with relapsed or refractory peripheral T‐cell lymphoma: results of the pivotal phase II BELIEF (CLN‐19) study. J Clin Oncol. 2015; 33: 2492 – 2499. | |
dc.identifier.citedreference | Pro B, Advani R, Brice P, et al. Brentuximab vedotin (SGN‐35) in patients with relapsed or refractory systemic anaplastic large‐cell lymphoma: results of a phase II study. J Clin Oncol. 2012; 30: 2190 – 2196. | |
dc.identifier.citedreference | Younes A, Gopal AK, Smith SE, et al. Results of a pivotal phase II study of brentuximab vedotin for patients with relapsed or refractory Hodgkin’s lymphoma. J Clin Oncol. 2012; 30: 2183 – 2189. | |
dc.identifier.citedreference | Fanale MA, Horwitz SM, Forero‐Torres A, et al. Brentuximab vedotin in the front‐line treatment of patients with CD30+ peripheral T‐cell lymphomas: results of a phase I study. J Clin Oncol. 2014; 32 ( 28 ): 3137 – 3143. | |
dc.identifier.citedreference | Bellei M, Foss FM, Horwitz SM, et al. The Outcome of Patients with Primary Refractory or Relapsed Peripheral T‐Cell Lymphoma: Analysis of 1020 Cases Registered in the Prospective T‐Cell Project [abstract]. American Society of Hematology. San Diego, CA; 2016. | |
dc.identifier.citedreference | Wang C, McKeithan TW, Gong Q, et al. IDH2R172 mutations define a unique subgroup of patients with angioimmunoblastic T‐cell lymphoma. Blood. 2015; 126 ( 15 ): 1741 – 1752. | |
dc.identifier.citedreference | Vallois D, Dobay MP, Morin RD, et al. Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T‐cell‐derived lymphomas. Blood. 2016; 128 ( 11 ): 1490 – 1502. | |
dc.identifier.citedreference | Vaque JP, Gomez‐Lopez G, Monsalvez V, et al. PLCG1 mutations in cutaneous T‐cell lymphomas. Blood. 2014; 123 ( 13 ): 2034 – 2043. | |
dc.identifier.citedreference | Iqbal J, Wright G, Wang C, et al. Gene expression signatures delineate biological and prognostic subgroups in peripheral T‐cell lymphoma. Blood. 2014; 123 ( 19 ): 2915 – 2923. | |
dc.identifier.citedreference | Wang T, Feldman AL, Wada DA, et al. GATA‐3 expression identifies a high‐risk subset of PTCL, NOS with distinct molecular and clinical features. Blood. 2014; 123 ( 19 ): 3007 – 3015. | |
dc.identifier.citedreference | Heavican TB, Yu J, Bouska A, et al. Molecular Subgroups of Peripheral T‐Cell Lymphoma Evolve by Distinct Genetic Pathways [Abstract]. San Diego, CA: American Society of Hematology; 2016. | |
dc.identifier.citedreference | Elenitoba‐Johnson KS, Wilcox R. A new molecular paradigm in mycosis fungoides and Sezary syndrome. Semin Diagn Pathol. 2017; 34 ( 1 ): 15 – 21. | |
dc.identifier.citedreference | Wilcox RA. A three‐signal model of T‐cell lymphoma pathogenesis. Am J Hematol. 2016; 91 ( 1 ): 113 – 122. | |
dc.identifier.citedreference | Reimer P. Impact of autologous and allogeneic stem cell transplantation in peripheral T‐cell lymphomas. Adv Hematol. 2010; 2010: 320624. | |
dc.identifier.citedreference | Vose J, Armitage J, Weisenburger D. International peripheral T‐cell and natural killer/T‐cell lymphoma study: pathology findings and clinical outcomes. J Clin Oncol. 2008; 26 ( 25 ): 4124 – 4130. | |
dc.owningcollname | Interdisciplinary and Peer-Reviewed |
Files in this item
Remediation of Harmful Language
The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.
Accessibility
If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.